Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Table 4 Factors associated with overall survival in patients with brain metastases

Factor	Median (months)	CI (95%)	Univariate analysis	RR	CI (95%)	Multivariate analysis
			p ^§			p^§
Gender
Male	6.9	(5.9 -8.1)	0.05	0.65	(0.37 -1.3)	0.129
Female	11.3	(4.4 -18.1)
Age
<55	8.2	(4.3 -12.1)	0.44
≥55	8.4	(3.5 -13.4)
KPS
<80	5.1	(0 - 10.4)	0.1	0.8	(0.48 -1.3)	0.38
≥80	12.4	(4.9 -19.9)
Number of metastases
<4	13.5	(9.6 -17.4)	0.002	1.9	(1.12 -3.3)	0.017
≥4	2.9	(1.1- 4.8)
Histology
NSCLC and others	7.9	(3.8 -11.9)	0.67
Breast cancer	4.5	(1.9 -17)
Time of brain metastasis
During primary tumor diagnosis	10.2	(4.3-16)	0.743
During recurrence	8.2	(3.9-12.5)
Treatment
Control arm	7.42	(3.8 -11)	0.637
CLQ arm	10.1	(4.9 -15.3)

Abbreviations: SE standard error, KPS Karnofsky performance status, NSCLC non-small-cell lung cancer, CHT chemotherapy, CLQ chloroquine. ^§P log-rank test.

ISSN: 1748-717X